Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) EBT (2016 - 2025)

Historic EBT for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to -$65.2 million.

  • Ocular Therapeutix's EBT fell 3313.13% to -$65.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$263.5 million, marking a year-over-year decrease of 5962.16%. This contributed to the annual value of -$263.5 million for FY2025, which is 5962.16% down from last year.
  • Latest data reveals that Ocular Therapeutix reported EBT of -$65.2 million as of Q4 2025, which was down 3313.13% from -$68.0 million recorded in Q3 2025.
  • Ocular Therapeutix's 5-year EBT high stood at -$19.5 million for Q1 2022, and its period low was -$68.0 million during Q3 2025.
  • In the last 5 years, Ocular Therapeutix's EBT had a median value of -$22.9 million in 2022 and averaged -$34.4 million.
  • Its EBT has fluctuated over the past 5 years, first skyrocketed by 1094.77% in 2022, then plummeted by 11550.88% in 2024.
  • Quarter analysis of 5 years shows Ocular Therapeutix's EBT stood at -$19.7 million in 2021, then dropped by 5.38% to -$20.8 million in 2022, then decreased by 9.42% to -$22.7 million in 2023, then plummeted by 115.51% to -$49.0 million in 2024, then tumbled by 33.13% to -$65.2 million in 2025.
  • Its EBT stands at -$65.2 million for Q4 2025, versus -$68.0 million for Q3 2025 and -$67.2 million for Q2 2025.